Three new clinical trials presented at the American Diabetes Association's annual meeting in New Orleans reveal a promising combination therapy: cagrilintide paired with semaglutide can drive blood sugar control to levels that have long eluded patients and their doctors.
The findings matter because type 2 diabetes remains one of the world's most stubborn metabolic challenges, particularly for people who haven't responded adequately to existing medications. Despite taking metformin, injectable insulin, and other agents, many patients still struggle to reach the target blood sugar levels that protect them from heart disease, kidney damage, and other serious complications. This new two-drug approach offers real hope to what researchers call "a challenging population"—those with persistent, difficult-to-control diabetes.
In the first trial, led by Vanita R. Aroda of Brigham and Women's Hospital in Boston, 62 patients received the combination therapy at its highest dose (2.4 mg each of cagrilintide and semaglutide) once weekly. After 40 weeks, their hemoglobin A1c—the gold-standard measure of long-term blood sugar control—dropped by 1.8 percentage points. That's substantially better than the 0.1 percentage point decline in the placebo group, and it represents a shift toward healthier ranges for many patients.
The largest trial, conducted by John B. Buse of the University of North Carolina School of Medicine, enrolled 2,713 adults over 68 weeks and compared the combination therapy directly against semaglutide alone. The results were clear: cagrilintide-semaglutide reduced HbA1c by 1.91 percentage points, compared to 1.75 percentage points for semaglutide alone. While the difference is modest, it suggests that adding cagrilintide—an amylin receptor agonist, a class of medicine that works through a different biological pathway—genuinely amplifies the effect.
The most striking results came from the third study, led by Julio Rosenstock at the University of Texas Southwestern Medical Center. Among 274 patients already using basal insulin, the highest-dose combination achieved a 2.33 percentage point drop in HbA1c, with the lower dose delivering a 2.33 percentage point reduction as well. Compared to placebo's 0.66 percentage point decline, these are transformative changes that could push patients' blood sugar below the 7 percent target that clinicians have long aimed for.
Cagrilintide is an amylin receptor agonist—a synthetic version of a hormone that helps regulate appetite and blood sugar in tandem with insulin. By pairing it with semaglutide (a GLP-1 receptor agonist that slows digestion and increases insulin release), researchers appear to have unlocked a synergistic effect: two different biological mechanisms working together to achieve better control than either alone.
All three trials were published in June 2026 in The Lancet and The Lancet Diabetes & Endocrinology. It's worth noting that Novo Nordisk, the pharmaceutical company developing cagrilintide, funded the studies—a detail that should inform how readers weigh the enthusiasm. Yet the scale and rigor of these trials, conducted by respected academic researchers across multiple sites, suggest findings worth taking seriously.
For patients struggling to manage their diabetes despite everything their doctors have tried, this combination represents a tangible new option. Whether it becomes a standard part of care will depend on ongoing safety monitoring and real-world effectiveness, but early signals are unmistakably positive.